MindMaze Therapeutics

V6M.FApproved

Lausanne, SwitzerlandFounded 2012mindmazetherapeutics.com

MindMaze Therapeutics has established itself as a leader in developing integrated neurotherapeutic combinations, merging behavior, software, devices, and data analytics into a cohesive treatment ecosystem. The company's commercially available platform, including MindMotion GO and the MindPod immersive gaming environment, is already impacting patient lives through deployments in clinical and home settings. With a focus on precision neurotherapeutics for rare diseases and a robust pipeline of digital motion assessment tools, MindMaze is redefining brain health recovery by leveraging proprietary technology to capture and analyze digital biomarkers.

Market Cap

$6.8M

Founded

2012

Focus

BiologicsRNA & Gene Therapy

V6M.F · Stock Price

USD 0.472.45 (-83.96%)

Historical price data

AI Company Overview

Technology Platform

An integrated neurotherapeutic platform combining immersive digital experiences (VR/gaming), behavioral software, smart medical peripherals, and 3D motion capture analytics to create personalized treatment ecosystems for brain recovery.

Opportunities

Significant growth opportunities exist in expanding the clinical evidence and insurance reimbursement for its approved digital therapeutic systems into new neurological indications and geographic markets.

The Physilog digital biomarker platform presents a major opportunity for partnerships with pharmaceutical companies to enhance clinical trials for neurological drugs.

Furthermore, the company's internal rare disease drug development program could yield high-value assets if successfully advanced.

Risk Factors

Key risks include the ongoing challenge of securing widespread and stable insurance reimbursement for digital therapeutics, the need for continuous generation of high-level clinical data to support adoption, intense competition in the rapidly evolving neuro-digital health space, and the operational complexity of scaling a global hardware/software platform business while advancing a drug pipeline.

Competitive Landscape

MindMaze competes with digital therapeutic companies like Akili Interactive and formerly Pear Therapeutics, as well as medical device firms in neurorehabilitation such as Hocoma and Bioventus. Its primary differentiation is its integrated ecosystem approach, combining immersive gaming for engagement, a validated home-use system for continuity of care, and quantitative motion analytics, all focused on solving the adherence and measurement challenges in long-term neurological recovery.